Stockscreener 앱 받기
4.56
0.44%
0.02
시간 외 거래:
4.55
-0.010
-0.22%
전일 마감가:
$4.54
열려 있는:
$4.575
하루 거래량:
4.71M
Relative Volume:
0.71
시가총액:
$985.77M
수익:
$76.20M
순이익/손실:
$-17.37M
주가수익비율:
501.10
EPS:
0.0091
순현금흐름:
$-75.81M
1주 성능:
+7.29%
1개월 성능:
-2.56%
6개월 성능:
+33.72%
1년 성능:
+622.09%
1일 변동 폭
$4.39
$4.66
1주일 범위
$4.16
$4.66
52주 변동 폭
$0.61
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.56 | 981.44M | 76.20M | -17.37M | -75.81M | 0.0091 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Analysts bullish on CytomX Therapeutics (CTMX) as CTMX prices $250 million offering - MSN
CytomX Therapeutics (CTMX) making progress on key metastatic colorectal cancer treatment - MSN
CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress - Insider Monkey
CytomX Therapeutics (CTMX) gains analyst confidence on trial progress - MSN
Analysts Bullish on CytomX Therapeutics (CTMX) As CTMX Prices $250 Million Offering - Insider Monkey
10 Stocks Under $5 That Will Explode - Insider Monkey
How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data - Yahoo Finance
Jefferies raises CytomX Therapeutics (CTMX) price target to $16 - MSN
CytomX Therapeutics, Inc. (CTMX) latest stock news and headlines - Yahoo Finance Singapore
CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment - Insider Monkey
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Brokerages - marketbeat.com
Latest CTMX ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
CTMX Technical Analysis & ETF Price Forecast - Intellectia AI
CytomX Therapeutics (CTMX) price target increased by 47.30% to 13.90 - MSN
CTMX Stock Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026 - Meyka
CytomX Therapeutics Signals Progress in Varseta-M Trial - TipRanks
Aug Update: Does CytomX Therapeutics Inc have strong EBITDA marginsTreasury Yields & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
US Market Wrap: Is CytomX Therapeutics Inc a good stock for dollar cost averaging2026 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
CTMX Technical Analysis & Stock Price Forecast - Intellectia AI
CytomX Therapeutics launches $250M public offering - MSN
CytomX Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Aug Fed Impact: What hedge funds are buying CytomX Therapeutics Inc2026 Short Interest & Precise Swing Trade Entry Alerts - baoquankhu1.vn
CTMX stock rallies on strong phase I colorectal cancer study data - MSN
Performance Recap: Is CytomX Therapeutics Inc stock showing strong momentum2026 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):